We recently reviewed the status of peptide and nonpeptide agonists and antagonists for the
V1a, V1b and V2 receptors for arginine vasopressin (AVP) and the oxytocin receptor for …

Central diabetes insipidus (CDI) is characterized by hypotonic polyuria due to impairment of
AVP secretion from the posterior pituitary. In clinical practice, it needs to be distinguished …

Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four
known receptors: The OT (uterine) and the AVP V 1a (vasopressor), V 1b (pituitary), V 2 …

Human neurohormone vasopressin (AVP) is synthesized in overlapping regions in the
hypothalamus. It is mainly known for its vasoconstricting abilities, and it is responsible for the …

Desmopressin (dDAVP), a synthetic analog of the neurohypophyseal nonapeptide arginine
vasopressin, has enhanced antidiuretic potency, markedly diminished pressor activity, and a …

Desmopressin is a vasopressin analogue selective for type 2 vasopressin receptors that
mediate renal water retention. In contrast to the native hormone arginine vasopressin, a well …

Summary objective We assessed the ability of desmopressin to stimulate the pituitary‐
adrenal axis in patients with Cushing's syndrome. DESIGN AND SUBJECTS The Cortisol …

The treatment of central diabetes insipidus has not changed significantly in recent decades,
and dDAVP and replacement of free water deficit remain the cornerstones of treatment. Oral …

To assess the ability of desmopressin to differentiate between pituitary and ectopic ACTH-
dependent Cushing's syndrome and to determine whether diagnostic accuracy could be …

As part of our studies on the design and synthesis of antagonists of the vasopressor
response to arginine-vasopressin (AVP), we have synthesized [l-(d-mercapto-/3, J …